Quantitative Benefit-Risk Analysis for Evaluating Drug Therapies

REFERENCES

• Andrews , J. R. ( 1985 ). Benefit, risk, and optimization by ROC analysis in cancer radiotherapy . International Journal Radiation Oncology-Biology-Physics 11 : 1557 – 1562 .
   PubMed Web of Science ®Google Scholar
• Congressional Budget Office, Congress of the United States . ( 2007 ). Research on the Comparative Effectiveness of Medical Treatments . Pub. no. 2975 . Washington , DC : Congressional Budget Office, December .
   Google Scholar
• Delongchamp , R. R. , Bowyer , J. F. , Chen , J. J. , Kodell , R. L. ( 2004 ). Multiple-testing strategy for analyzing cDNA array data on gene expression . Biometrics 60 : 774 – 782 .
   PubMed Web of Science ®Google Scholar
• Donaldson , C. , Baker , R. , Mason , H. , Jones-Lee , M. , Lancsar , E. , Wildman , J. , Bateman , I. , Loomes , G. , Robinson , A. , Sugden , R. , Pinto Prades , J. L. , Ryan , M. , Shackley , P. , Smith , R. ( 2011 ). The social value of a QALY: Raising the bar or barring the raise? BMC Health Services Research 11 : 8 .
   PubMed Web of Science ®Google Scholar
• Entsuah , R. , Gao , B. ( 2002 ). Global benefit–risk evaluation of antidepressant action: Comparison of pooled data for Venlafaxine, SRRIs and placebo . CNS Spectrums 7 : 882 – 888 .
   PubMedGoogle Scholar
• Food and Drug Administration . ( 2011 ). Draft Guidance for Industry and Food and Drug Administration Staff, Factors to Consider when Making Benefit–Risk Determinations in Medical Device Premarket Review. August 15. Available at www.fda.gov/MedicalDevices/DeviceReglationandGuidance/GuidanceDocuments/ucm267829.htm
   Google Scholar
• Garrison , L. P. , Jr. , Towse , A. , Bresnahan , B. W. ( 2007 ). Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis . Health Affairs 26 : 684 – 695 .
   Web of Science ®Google Scholar
• Holden , W. L. , Juhaeri , J. , Dai , W. ( 2003 ). Benefit–risk analysis: A proposal using quantitative methods . Pharmacoepidemiology and Drug Safety 12 : 611 – 616 .
   PubMed Web of Science ®Google Scholar
• Kodell , R. L. , Chen , J. J. ( 2010 ). Is premarket identification of hepatotoxic drugs and sensitive patients possible based on high-dimensional ‘omic data? Personalized Medicine 7 : 171 – 178 .
   PubMed Web of Science ®Google Scholar
• Moore , D. H. , Mendelsohn , M. L. ( 1972 ). Optimal treatment levels in cancer therapy . Cancer 30 : 97 – 106 .
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence . ( 2011 ). Guide to the Methods of Technology Appraisal. Available at www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed September 21, 2011) .
   Google Scholar
• O'Neill , R. T. ( 2008 ). A perspective on characterizing benefits and risks derived from clinical trials: Can we do more? Drug Information Journal 42 : 235 – 245 .
   Web of Science ®Google Scholar
• Phillips , C. (2009). What is a QALY? Hayward Medical Communications. Available at www.whatisseries.co.uk (accessed September 21, 2011).
   Google Scholar
• Shaffer , M. L. , Watterberg , K. L. ( 2006 ). Joint distribution approaches to simultaneously quantifying benefit and risk . BMC Medical Research Methodology 6 : 48 .
   PubMedGoogle Scholar
• Shukovsky , L. J. , Baeza , M. R. , Fletcher , G. H. ( 1976 ). Results of irradiation in squamous cell carcinomas of the glossopalatine sulcus . Radiology 120 : 405 – 408 .
   PubMed Web of Science ®Google Scholar
• Zweig , M. H. , Campbell , G. ( 1993 ). Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine . Clinical Chemistry 39 : 561 – 577 .
   PubMed Web of Science ®Google Scholar
• The views expressed in this article do not necessarily represent those of the U.S. Food and Drug Administration.
   Google Scholar